Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. SOTHEMA's pretax income for the
six
months ended in Dec. 2025 was MAD322 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was MAD625 Mil.
SOTHEMA's pretax margin was 19.19%.
During the past 13 years, SOTHEMA's highest Pretax Margin was 19.82%. The lowest was 15.42%. And the median was 18.18%.
During the past 13 years, SOTHEMA's highest Pretax Margin was 19.82%. The lowest was 15.42%. And the median was 18.18%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA Pre-Tax Income Related Terms
SOTHEMA Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for SOTHEMA's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS:SOT vs LLY, JNJ, ABBV: Pre-Tax Income Comparison
For the Drug Manufacturers - General subindustry, SOTHEMA's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA Pre-Tax Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where SOTHEMA's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD625 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a Pre-Tax Income of MAD625 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on SOTHEMA and its competitors.
Is SOTHEMA's Pre-Tax Income too high?
SOTHEMA's current Pre-Tax Income is MAD625 Mil. Overall, SOTHEMA has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's Pre-Tax Income compare to LLY and JNJ?
SOTHEMA's Pre-Tax Income of MAD625 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on SOTHEMA and its competitors. SOTHEMA's current Pre-Tax Income is MAD625 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Modestly Overvalued. The stock's GF Value™ is MAD290.58, compared to a current price of MAD364.90 — trading 25.6% above its estimated fair value. The current Pre-Tax Income is MAD625 Mil. SOTHEMA's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current Pre-Tax Income is MAD625 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD364.90 is trading 25.6% above its estimated GF Value™ of MAD290.58.
GuruFocus considers SOTHEMA to be Modestly Overvalued.
Key valuation signals for CAS:SOT:
Pre-Tax Income: MAD625 Mil
GF Value™: MAD290.58 vs. price of MAD364.90 (25.6% above fair value)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
68GF Score
Get the complete analysis for CAS:SOT
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
